Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 424-432

  Baldwin, S J ^a   Clarke, S E ^a   Chenery, R J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CYP2C8; Human liver microsomes; Rosiglitazone

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DRUG METABOLITE; FURAFYLLINE; ISOTRETINOIN; KETOCONAZOLE; ORAL ANTIDIABETIC AGENT; OXYGENASE; PACLITAXEL; QUINIDINE; ROSIGLITAZONE; SB 243914; SB 244675; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER MICROSOME; METABOLIC RATE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; MICROSOMES, LIVER; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; THIAZOLES; THIAZOLIDINEDIONES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032818309     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00030.x     Document Type: Article

References (34)

1. Cawthorne MA, Lister CA, Holder JC, et al. Anti-hyperglycacmic efficacy of BRL 49653, a highly potent thiazolidinedione, in animal models of non-insulin dependent diabetes. Diabetes 1993; 42: 204A.
2. McInnes GT, Brodic MJ. Drug interactions that matter. A critical appraisal. Drugs 1988; 36: 83-110.
3. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
4. Bolton GC, Keogh JP, East PD, Hollis FJ, Shore AD. The fate of a thiazolidinedione antidiabetic agent in rat and dog. Xenobiotica 1996; 26: 627-636.
5. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br J Clin Pharmacol 1990; 29: 651-663.
6. Clarke SE, Ayrton AD, Chenery RJ. Characterisation of the inhibition of Cytochrome P4501A2 by furafylline. Xenobiotica 1994; 24: 517-526.
7. Leo MA, Lasker JM, Raucy JL, Kim C, Black M, Lieber CS. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch Biochem Biophys 1989; 269: 305-312.
8. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
9. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debdsoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Therap 1988; 247: 242-247.
10. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. Faseb J 1992; 6: 752-758.
11. Berthou F, Flinois J-P, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1991; 19: 561-567.
12. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322-1329.
13. Maurice M, Emiliani S, Dalet-Beluche I, Derancourt J, Lange R. Isolation and characterisation of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 1991; 200: 511-517.
14. Rahman A, Korzekwa R, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-5546.
15. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533-538.
16. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252: 442-447.
17. Wrighton SA, Stevens JC, Becker GW, Vandenbranden M. Isolation and characterisation of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240-245.
18. Zanger UM, Vilbois F, Hardwick J, Meyer UA. Absence of hepatic cytochrome P450buf 1 causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447-5454.
19. Clarke SE, Baldwin SJ, Bloomer JC, Ayrton AD, Sozio RS, Chenery RJ. Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem Res Tox 1994; 7: 836-842.
20. Combalbert J, Fabre I, Fabre I, et al. Metabolism of Cyctosporin A. Purification and identification of the rifampicin-inducible human liver cytochrome P 450 (Cyclosporin A Oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
21. Dirven HAAM, Peters JGP, Gibson GG, Peters WHM, Jongeneelen FJ. Lauric acid hydroxylase activity and cytochrome P450 IV family proteins in human liver microsomes. Biochem Pharmacol 1991; 42: 1841-1844.
22. 14C-methyl] caffeine. Xenobiotica 1995; 25: 917-927.
23. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes, kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37: 1137-1144.
24. Meier UT, Kronbach T, Meyer UA. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem 1985; 151: 286-291.
25. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (Cyclosporin A Oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606.
26. Poon GK, Wade J, Bloomer JC, Clarke SE, Maltas J. Rapid screening of taxol metabolites in human microsomes by liquid chromatography/electrospray ionization-mass spectrometry. Rapid Commun Mass Spectrom 1996; 10: 1165-1168.
27. Leatherbarrow RJ. Grafit 1992 Version 3.0, Erithacus Software Ltd., Staines, UK.
28. SAS./INSIGHT®. Users Guide 1993 Version 6, 2nd edn, SAS Institute Inc., SAS Campus Drive, Cary, NC 27513.
29. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 1998; 87: 1502-1507.
30. Crespi CL. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 1995; 26: 179-235.
31. Cresteil T, Monsarrat B, Alvineric P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isoenzymes involved in its metabolism. Cancer Res 1994; 54: 386-392.
32. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566-575.
33. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26: 23-29.
34. Woifgang M. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998; 56: 15-23.